Saskia Brachmann

Company: Novartis AG

Job title: Associated Director

Seminars:

Leveraging JDQ443 to Face New Challenges & Utilize Opportunities in Treating KRAS G12C Mutant Cancers 4:00 pm

Elucidating the latest preclinical and clinical data on JDQ443, a promising inhibitor of KRAS G12C mutant cancer cells, resulting in improved therapeutic outcomes Overcoming emerging mechanisms of resistance to KRAS G12C-targeted therapy and how JDQ443 offers a potential solution to overcoming these challenges Advancing combination treatments to explore the opportunities for combining JDQ443 with other…Read more

day: Conference Day Two